id,disease_progression_status,survival_status,clinical_response_rate_target_lasion,clinical_response_rate_non_target_lasion,clinical_response_rate_new_lasion,clinical_response_rate_result,radiological_response_rate_target_lasion,radiological_response_rate_non_target_lasion,radiological_response_rate_new_lasion,radiological_response_rate_result,pathological_response_rate_target_lasion,pathological_response_rate_non_target_lasion,pathological_response_rate_new_lasion,pathological_response_rate_result,time,registration_number,laterality,current_chemo_protocol,chemo_starting_date,chemo_cycle_no,chemo_detail,disease_progression_status_date,pfs,survival_status_date,overall_survival,clinical_response_rate_date,radiological_response_rate_date,pathological_response_rate_date,cancer_type,patient_id_id,patient_id_socio_economic_status_name,patient_id_unique_id,patient_id_name,patient_id_phone,patient_id_date_of_birth,patient_id_gender,patient_id_blood_group,patient_id_area,patient_id_police_station,patient_id_district,doctor_id_name,center_id_name,grade_name,line_of_treatment_name,diagnosis_disease_group_name,diagnosis_subgroup_diagnosis_disease_group_name,diagnosis_subgroup_name,diagnosis_primary_site_name,diagnosis_laterility_name,patient_id_socio_economic_status,grade,disease_progression_status_name,survival_status_name,clinical_response_rate_target_lasion_name,clinical_response_rate_non_target_lasion_name,clinical_response_rate_new_lasion_name,clinical_response_rate_result_name,radiological_response_rate_target_lasion_name,radiological_response_rate_non_target_lasion_name,radiological_response_rate_new_lasion_name,radiological_response_rate_result_name,diagnosis_laterility,line_of_treatment,diagnosis_subgroup,pathological_response_rate_target_lasion_name,pathological_response_rate_non_target_lasion_name,pathological_response_rate_new_lasion_name,pathological_response_rate_result_name,diagnosis_disease_group,diagnosis_primary_site,name,value,unit,date,patient_observation_id
35,,,,,,,,,,,,,,,2024-05-02T17:52:01+06:00,BSH - H12310386329,,Trastuzumab,2024-04-04,1.0,"Received 4 cycles NAChT with AC from 01.08.23 to 03.10.23 (at Dhaka Cancer H)>
Surgery> Started Adjuvant Cycle 5 with Docetaxel + Trastuzumab from 27.11.23. C8 completed on 29.01.24
Maintenance 7 Trastuzumab due on 04.04.2024",2024-04-03,,2024-04-04,,2023-10-25,,,Breast,32,Upper middle class,BSBSC-240000032,AFRUJA KHATUN,1893090740,1975-02-08,Female,,,,,Dr Md Arifur Rahman,BSH,2.0,Continuous Maintenance,C50- Malignant neoplasm of breast,C50- Malignant neoplasm of breast,C50.3- Lower-inner quadrant of breast,Breast,Left,,,Stable,Alive,CR,,,,,,,,,,,,,,,,,,,,,
315,,,,,,,,,,,,,,,2024-06-15T12:33:27+06:00,BSH - H12310386329,Left,Trastuzumab,2024-04-04,1.0,"Received 4 cycles NAChT with AC from 01.08.23 to 03.10.23 (at Dhaka Cancer H)>
Surgery> Started Adjuvant Cycle 5 with Docetaxel + Trastuzumab from 27.11.23. C8 completed on 29.01.24
Maintenance 7 Trastuzumab due on 04.04.2024",2024-04-03,,2024-04-04,,2023-10-25,,,Breast,32,Upper middle class,BSBSC-240000032,AFRUJA KHATUN,1893090740,1975-02-08,Female,,,,,Dr Md Arifur Rahman,BSH,2.0,Continuous Maintenance,C50- Malignant neoplasm of breast,C50- Malignant neoplasm of breast,C50.3- Lower-inner quadrant of breast,Breast,Left,,,Stable,Alive,CR,,,,,,,,,,,,,,,,,,,,,
